Navigation Links
New test detects early-stage, asbestos-related pulmonary cancer
Date:4/4/2011

Researchers at NYU Langone Medical Center have investigated a novel protein test to detect early-stage, asbestos-related pulmonary cancer. The test can accurately identify proteins secreted from cancerous tumors caused by asbestos exposure. The study was presented at the American Association for Cancer Research 102nd Annual Meeting 2011 on April 4th.

In a blinded test performed under the sponsorship of the National Cancer Institute's Early Detection Research Network Biomarker Discovery Lab, researchers detected 15 of 19 cases of stage 1 or stage 2 malignant pleural mesothelioma. The study shows the test is approximately 80 percent sensitive in identifying disease. In addition, the specificity of the test was 100 percent with no false positives.

Malignant pleural mesothelioma is an aggressive, asbestos-related pulmonary cancer that develops in the lining of the lungs. Each year, the disease causes an estimated 15,000 to 20,000 deaths worldwide. It can be fatal within 14 months following diagnosis because of the advanced stage that it is typically found.

The goal of a new diagnostic test is to find the cancer early enough to effectively treat it, according to Harvey I. Pass, MD, director of the Division of Thoracic Surgery and Thoracic Oncology at NYU Langone Medical Center and the NYU Cancer Institute.

"The only patients that seem to benefit from therapy in mesothelioma are those that are found in stage 1, and this is only 10 to 15 percent of patients," said lead researcher Dr. Pass. "Moreover, when found early, the magnitude of the operation necessary to reduce the burden of disease may be less, making the patient better able to cope if the disease recurs and the patient needs more aggressive therapy."

The research team used the "Multiplex SOMAmer Assay" by SomaLogic, Inc. to examine 170 blood samples from 90 patients diagnosed with malignant mesothelioma and 80 participants who were previously exposed to asbestos. The technology uses SOMAmers, chemically modified single-stranded DNA molecules to bind specifically to target proteins , to identify and quantify biomarkers.

According to Dr. Pass, this test measures 19 protein biomarkers for malignant pleural mesothelioma and is able to find and quantify the small amount of proteins secreted by tumor cells. Ongoing studies are refining the test and validating the results in other patient blood samples.


'/>"/>

Contact: Lauren Woods
lauren.woods@nyumc.org
212-404-3753
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Related medicine news :

1. In Tests, Implanted Monitor Detects Atrial Fibrillation
2. Nanotech breath sensor detects diabetes and potentially serious complication
3. Molecular imaging detects recurrent prostate cancer
4. Eat safer: Novel approach detects unknown food pathogens
5. Color-changing blast badge detects exposure to explosive shock waves
6. Electronic nose detects cancer
7. MEMS thermal sensor detects pre-atherosclerotic lesions
8. Simple blood test detects early emphysema in smokers before symptoms appear
9. In pilot study, screening detects potentially serious heart conditions in healthy children
10. Vaccine for Asbestos-Related Cancer Looks Safe
11. United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., ... From Not to Hot,” which will begin airing on February 24, 2017. The show ... from the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, ... symposium on “Doping in Sport: How the Culture Might Change,” in ... LLP. The symposium will be held at Pepperdine University in Malibu, California. , ...
(Date:2/23/2017)... ... 2017 , ... Current Meditation , a new meditation ... the U.S. starting this spring. Current Meditation focuses on “meditation for the modern ... Meditation will be the first meditation concept in the U.S. offering franchising opportunities, ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... CALNOC, the ... FACMPE, FACPE, will keynote their upcoming conference – Empowerment, Value and Collaboration – in ... chairman and CEO of the Virginia Mason Health System in Seattle since 2000. In ...
(Date:2/23/2017)... ... 2017 , ... Thomas Vas-Don suffered from severe injury due to ... able to successfully recover. In “ Origin & Insertion Charts for Massage Therapists ” ... principals of massage, anatomy , trigger points and referral pain patterns . ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 ... gives comprehensive insights on the various drugs ... The report covers all the drugs that ... Preclinical & Clinical). The pipeline focuses on ... small molecules, antibodies, stem cell therapies, recombinant ...
(Date:2/24/2017)... STOCKHOLM , Feb 24, 2017 ... Nomination Committee,s proposal for a new Board of Directors ... Meeting. The 2016-2017 Nomination Committee comprises representatives of the ... third quarter of 2016 who have accepted a seat ... Board. The composition of the 2016-2017 Nomination Committee was ...
(Date:2/24/2017)... 2017 Research and Markets has announced the ... - 2016" report to their offering. ... The latest research Urinary Incontinence Drugs ... benchmarks in the global Urinary Incontinence market. The research answers ... key drugs marketed for Urinary Incontinence and their clinical attributes? How ...
Breaking Medicine Technology: